Suchergebnisse - "Myeloma"

PubPharm (15)

1

Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance : a retrospective study

enthalten in: International journal of hematology | 2019

von Kuwabara, C. | Sakuma, Y. | Kume, A. | +5

2

Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study

enthalten in: International journal of hematology | 2018

von Kuwabara, c. | Sakuma, Y. | Kume, A. | +5

3

Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study

enthalten in: International journal of hematology | 2018

von Kuwabara, c. | Sakuma, Y. | Kume, A. | +5

4

Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study

enthalten in: International journal of hematology | 2018

von Kuwabara, c. | Sakuma, Y. | Kume, A. | +5

5

Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma

enthalten in: Journal of clinical oncology | January 17, 2018

von Siegel, D. | Dimopoulos, M. | Ludwig, H. | +7

6

Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation

enthalten in: European journal of nuclear medicine and molecular imaging | January 2017

von Sachpekidis, C. | Hillengaß, J. | Goldschmidt, H. | +4

7

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study

enthalten in: The lancet / Oncology | 2016

von Dimopoulos, M. | Goldschmidt, H.

8

Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation

enthalten in: Clinical cancer research | May 2009

von Hillengaß, J. | Zechmann, C. | Bäuerle, T. | +10

9

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma : impact of a dose-modification guideline

enthalten in: British journal of haematology | 19 February 2009

von Richardson, P. | Sonneveld, P. | Schuster, M. | +16

10

Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)

enthalten in: Bone marrow transplantation | 24 September 2007

von Hundemer, M. | Klein, U. | Hose, D. | +8